What is the level of liabilities of Genscript Biotech this year?
Genscript Biotech has a debt balance of 0 USD this year.
In 2024, Genscript Biotech's total liabilities amounted to 0 USD, a -100% difference from the 1.54 B USD total liabilities in the previous year.
Genscript Biotech's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Genscript Biotech's financial stability, operational efficiency, and long-term viability.
By comparing Genscript Biotech's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Genscript Biotech's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Shifts in Genscript Biotech’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Genscript Biotech has a debt balance of 0 USD this year.
The liabilities of Genscript Biotech have increased by -100% dropped compared to the previous year.
High liabilities can pose a risk for investors of Genscript Biotech, as they can weaken the company's financial position and impair its ability to meet its obligations.
Low liabilities mean that Genscript Biotech has a strong financial position and is able to meet its obligations without overburdening its finances.
An increase in liabilities of Genscript Biotech can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
A decrease in the liabilities of Genscript Biotech can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
Some factors that can influence the liabilities of Genscript Biotech include investments, acquisitions, operating costs, and sales development.
The liabilities of Genscript Biotech are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
To change its liabilities, Genscript Biotech can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
Over the past 12 months, Genscript Biotech paid a dividend of 0.01 USD . This corresponds to a dividend yield of about 0.72 %. For the coming 12 months, Genscript Biotech is expected to pay a dividend of 0 USD.
The current dividend yield of Genscript Biotech is 0.72 %.
Genscript Biotech pays a quarterly dividend. This is distributed in the months of .
Genscript Biotech paid dividends every year for the past 4 years.
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
Genscript Biotech is assigned to the 'Health' sector.
To receive the latest dividend of Genscript Biotech from 6/21/2017 amounting to 0.012 USD, you needed to have the stock in your portfolio before the ex-date on 6/5/2017.
The last dividend was paid out on 6/21/2017.
In the year 2023, Genscript Biotech distributed 0 USD as dividends.
The dividends of Genscript Biotech are distributed in USD.
Our stock analysis for Genscript Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genscript Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.